Variability in the Androgen Response of Prostate Epithelium to 5α-Reductase Inhibition: Implications for Prostate Cancer Chemoprevention
Open Access
- 14 February 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (4) , 1286-1295
Abstract
Inhibitors of 5α-reductase (SRD5A) that lower intraprostatic levels of dihydrotestosterone (DHT) reduce the overall incidence of prostate cancer (PCa), but there is significant variation in chemopreventive activity between individual men. In seeking molecular alterations that might underlie this variation, we compared gene expression patterns in patients with localized PCa who were randomized to prostatectomy alone versus treatment with two different doses of the SRD5A inhibitor dutasteride. Prostatic levels of DHT were decreased by >90% in both dutasteride-treated patient groups versus the untreated patient group. Despite significant and uniform suppression of tissue DHT, unsupervised clustering based on prostatic gene expression did not discriminate these groups. However, subjects could be resolved into distinct cohorts characterized by high or low expression of genes regulated by the androgen receptor (AR), based solely on AR transcript expression. The higher-dose dutasteride treatment group was found to include significantly fewer cancers with TMPRSS2-ERG genetic fusions. Dutasteride treatment was associated with highly variable alterations in benign epithelial gene expression. Segregating subjects based on expression of AR and androgen-regulated genes revealed that patients are differentially sensitive to SRD5A inhibition. Our findings suggest that AR levels may predict the chemopreventive efficacy of SRD5A inhibitors. Cancer Res; 70(4); 1286–95Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- Evidence for field cancerization of the prostateThe Prostate, 2009
- INCIDENCE OF BIOPSY-DETECTABLE PROSTATE CANCER IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL: BLINDED 2-YEAR RESULTSJournal of Urology, 2009
- The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate CancerJournal of Urology, 2008
- Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate CancerMolecular Endocrinology, 2008
- Novel 5α‐steroid reductase (SRD5A3, type‐3) is overexpressed in hormone‐refractory prostate cancerCancer Science, 2007
- A molecular correlate to the Gleason grading system for prostate adenocarcinomaProceedings of the National Academy of Sciences, 2006
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCERJournal of Urology, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001